NPCE Relative Valuation
NPCE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NPCE is overvalued; if below, it's undervalued.
Historical Valuation
Neuropace Inc (NPCE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.79. The fair price of Neuropace Inc (NPCE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：17.01
Fair
-25.78
PE
1Y
3Y
5Y
Trailing
Forward
-43.28
EV/EBITDA
Neuropace Inc. (NPCE) has a current EV/EBITDA of -43.28. The 5-year average EV/EBITDA is -13.74. The thresholds are as follows: Strongly Undervalued below -36.38, Undervalued between -36.38 and -25.06, Fairly Valued between -2.41 and -25.06, Overvalued between -2.41 and 8.91, and Strongly Overvalued above 8.91. The current Forward EV/EBITDA of -43.28 falls within the Strongly Undervalued range.
-30.00
EV/EBIT
Neuropace Inc. (NPCE) has a current EV/EBIT of -30.00. The 5-year average EV/EBIT is -10.84. The thresholds are as follows: Strongly Undervalued below -28.76, Undervalued between -28.76 and -19.80, Fairly Valued between -1.89 and -19.80, Overvalued between -1.89 and 7.07, and Strongly Overvalued above 7.07. The current Forward EV/EBIT of -30.00 falls within the Strongly Undervalued range.
5.75
PS
Neuropace Inc. (NPCE) has a current PS of 5.75. The 5-year average PS is 4.10. The thresholds are as follows: Strongly Undervalued below -1.20, Undervalued between -1.20 and 1.45, Fairly Valued between 6.76 and 1.45, Overvalued between 6.76 and 9.41, and Strongly Overvalued above 9.41. The current Forward PS of 5.75 falls within the Historic Trend Line -Fairly Valued range.
-63.42
P/OCF
Neuropace Inc. (NPCE) has a current P/OCF of -63.42. The 5-year average P/OCF is -13.09. The thresholds are as follows: Strongly Undervalued below -33.30, Undervalued between -33.30 and -23.19, Fairly Valued between -2.98 and -23.19, Overvalued between -2.98 and 7.13, and Strongly Overvalued above 7.13. The current Forward P/OCF of -63.42 falls within the Strongly Undervalued range.
-43.58
P/FCF
Neuropace Inc. (NPCE) has a current P/FCF of -43.58. The 5-year average P/FCF is -12.35. The thresholds are as follows: Strongly Undervalued below -29.87, Undervalued between -29.87 and -21.11, Fairly Valued between -3.59 and -21.11, Overvalued between -3.59 and 5.18, and Strongly Overvalued above 5.18. The current Forward P/FCF of -43.58 falls within the Strongly Undervalued range.
Neuropace Inc (NPCE) has a current Price-to-Book (P/B) ratio of 29.94. Compared to its 3-year average P/B ratio of 17.60 , the current P/B ratio is approximately 70.13% higher. Relative to its 5-year average P/B ratio of 12.32, the current P/B ratio is about 143.01% higher. Neuropace Inc (NPCE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.26%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -16.75% , the current FCF yield is about -100.00% lower.
30.50
P/B
Median3y
17.60
Median5y
12.32
-2.99
FCF Yield
Median3y
-15.26
Median5y
-16.75
Competitors Valuation Multiple
The average P/S ratio for NPCE's competitors is , providing a benchmark for relative valuation. Neuropace Inc Corp (NPCE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 29.89%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NPCE increased by 51.65% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -13.07 to -22.54.
The secondary factor is the Revenue Growth, contributed 29.89%to the performance.
Overall, the performance of NPCE in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Neuropace Inc (NPCE) currently overvalued or undervalued?
What is Neuropace Inc (NPCE) fair value?
How does NPCE's valuation metrics compare to the industry average?
What is the current P/B ratio for Neuropace Inc (NPCE) as of Dec 05 2025?
What is the current FCF Yield for Neuropace Inc (NPCE) as of Dec 05 2025?
What is the current Forward P/E ratio for Neuropace Inc (NPCE) as of Dec 05 2025?